Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.3% loss over the past four weeks.The stock rallied after the company announced positive top-line data from a phase II study evaluating its investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, in patients with acquired hypothalamic obesity. ...